Using etoposide + dexamethasone-based regimens to treat nasal type extranodal natural killer/T-cell lymphoma-associated hemophagocytic lymphohistiocytosis

被引：0
|
作者：
Liqiang Wei
Lei Yang
Jia Cong
Jin Ye
Xin Li
Na Yao
Jing Yang
Jing Ding
Jingwen Wang
机构：
[1] Beijing Tongren Hospital,Department of Hematology
[2] Capital Medical University,undefined
来源：
Journal of Cancer Research and Clinical Oncology | 2021年 / 147卷
关键词：
Extranodal NK/T-cell lymphoma, nasal type; Hemophagocytic lymphohistiocytosis; Chemotherapy; Etoposide; Dexamethasone;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：863 / 869
页数：6
相关论文
共 50 条
  • [21] Nasal-type extranodal natural killer/T-cell lymphoma presenting with a mass on the buttock A case report
    Liu, Shuzhong
    Zhou, Xi
    Song, An
    Huo, Zhen
    Wang, Yipeng
    Liu, Yong
    MEDICINE, 2019, 98 (49)
  • [22] Absolute lymphocyte count is a novel prognostic indicator in extranodal natural killer/T-cell lymphoma, nasal type
    Huang, J. J.
    Jiang, W. Q.
    Lin, T. Y.
    Huang, Y.
    Xu, R. H.
    Huang, H. Q.
    Li, Z. M.
    ANNALS OF ONCOLOGY, 2011, 22 (01) : 149 - 155
  • [23] Gemcitabine, dexamethasone, and cisplatin (GDP) chemotherapy with sandwiched radiotherapy in the treatment of newly diagnosed stage IE/IIE extranodal natural killer/T-cell lymphoma, nasal type
    Tian, Shu
    Li, Ruichen
    Wang, Tian
    Wang, Shengzi
    Tao, Rong
    Hu, Xichun
    Ding, Hao
    CANCER MEDICINE, 2019, 8 (07): : 3349 - 3358
  • [24] A phase 2 study of methotrexate, etoposide, dexamethasone, and pegaspargase chemotherapy for newly diagnosed, relapsed, or refractory extranodal natural killer/T-cell lymphoma, nasal type: a multicenter trial in Northwest China
    Liang, Rong
    Gao, Guang-xun
    Chen, Jie-ping
    Wang, Ji-shi
    Wang, Xiao-min
    Zeng, Yun
    Bai, Qing-xian
    Zhang, Tao
    Yang, Lan
    Dong, Bao-xia
    Gu, Hong-tao
    Shu, Mi-mi
    Hao, Cai-xia
    Wang, Jian-hong
    Zhang, Na
    Chen, Xie-qun
    HEMATOLOGICAL ONCOLOGY, 2017, 35 (04) : 619 - 629
  • [25] The Glasgow Prognostic Score (GPS) as a novel and significant predictor of extranodal natural killer/T-cell lymphoma, nasal type
    Li, Ya-Jun
    Jiang, Wen-Qi
    Huang, Jia-Jia
    Xia, Zhong-Jun
    Huang, Hui-Qiang
    Li, Zhi-Ming
    AMERICAN JOURNAL OF HEMATOLOGY, 2013, 88 (05) : 394 - 399
  • [26] The Impact of the Omission or Inadequate Dosing of Radiotherapy in Extranodal Natural Killer T-Cell Lymphoma, Nasal Type, in the United States
    Vargo, John A.
    Patel, Arisha
    Glaser, Scott M.
    Balasubramani, Goundappa K.
    Farah, Rafic J.
    Marks, Stanley M.
    Beriwal, Sushil
    CANCER, 2017, 123 (16) : 3176 - 3185
  • [27] First-line LVDP (L-asparaginase, etoposide, dexamethasone, and cisplatin) regimen combined with radiotherapy is effective for early-stage extranodal natural killer/T-cell lymphoma, nasal type
    Wu, Wanchun
    Chen, Xi
    Li, Na
    Luo, Qian
    Zou, Liqun
    ANNALS OF HEMATOLOGY, 2022, 101 (07) : 1557 - 1565
  • [28] A Phase II Study of Methotrexate, Etoposide, Dexamethasone and Pegaspargase Sandwiched with Radiotherapy in the Treatment of Newly Diagnosed, Stage IE to IIE Extranodal Natural-Killer/T-Cell Lymphoma, Nasal-Type
    Xu, Peng-Peng
    Xiong, Jie
    Cheng, Shu
    Zhao, Xia
    Wang, Chao-Fu
    Cai, Gang
    Zhong, Hui-Juan
    Huang, Heng-Ye
    Chen, Jia-Yi
    Zhao, Wei-Li
    EBIOMEDICINE, 2017, 25 : 41 - 49
  • [29] Penile metastasis secondary to nasal-type extranodal natural killer/T-cell lymphoma: A case report and review of the literature
    Li, Yanan
    Fu, Xiaorui
    Wu, Jingjing
    Yu, Chang
    Li, Zhaoming
    Sun, Zhenchang
    Yan, Jiaqin
    Nan, Feifei
    Zhang, Xundong
    Li, Ling
    Li, Xin
    Zhang, Lei
    Li, Wencai
    Wang, Guannan
    Zhang, Mingzhi
    ONCOLOGY LETTERS, 2018, 15 (05) : 8034 - 8038
  • [30] Decreased apolipoprotein A-I level indicates poor prognosis in extranodal natural killer/T-cell lymphoma, nasal type
    Quan, Qi
    Chen, Qi
    Chen, Ping
    Jiang, Li
    Li, Tingwei
    Qiu, Huijuan
    Zhang, Bei
    ONCOTARGETS AND THERAPY, 2016, 9 : 1281 - 1290
12345